Shukuya Takehito, Takahashi Toshiaki, Nakamura Yukiko, Yamamoto Nobuyuki
Division of Thoracic Oncology, Shizuoka Cancer Center.
Gan To Kagaku Ryoho. 2010 Mar;37(3):487-90.
We present a case of malignant pleural mesothelioma which responded to a cisplatin plus pemetrexed rechallenge. A 78- year-old man was diagnosed as stage IV malignant pleural mesothelioma in International Mesothelioma Interest Group (IMIG) stage by biopsy using ultrasonography and chest to abdominal CT. 6 courses of cisplatin at 60 mg/m2 plus pemetrexed at 500 mg/m2 were administered every 3 to 4 weeks. After this treatment, all of the lesions shrank, and the best overall response was partial response (PR) in Response Evaluation Criteria in Solid Tumors (RECIST). Although vinorelbine, gemcitabine and S-1 were administered subsequently because of the re-growth of the lesions, they were enlarged. Cisplatin plus pemetrexed was administered as fifth-line chemotherapy again, the lesions shrank, and the best overall response was PR in RECIST.
我们报告了一例对顺铂联合培美曲塞再次治疗有反应的恶性胸膜间皮瘤病例。一名78岁男性经超声引导下活检及胸部至腹部CT检查，被国际间皮瘤兴趣小组（IMIG）诊断为IV期恶性胸膜间皮瘤。每3至4周给予顺铂60mg/m²联合培美曲塞500mg/m²，共6个疗程。该治疗后，所有病灶均缩小，根据实体瘤疗效评价标准（RECIST），最佳总体反应为部分缓解（PR）。尽管后续因病灶复发给予长春瑞滨、吉西他滨和S-1治疗，但病灶仍增大。再次给予顺铂联合培美曲塞作为五线化疗，病灶缩小，根据RECIST，最佳总体反应为PR。
